18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology

University of Manitoba

Status and phase

Unknown

Phase 3

Conditions

Tumors

Treatments

Radiation: [18F]-Fluorodeoxyglucose

Study type

Interventional

Funder types

Other

Identifiers

NCT01180751

B2010:014

Details and patient eligibility

About

This clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test [Positron Emission Tomography (PET)scan] in adults who have or are suspected of having cancer and in another group of adults to assess for neurologic conditions.

Enrollment

1,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Known or suspected primary or metastatic tumours
A neurological presentation consistent with the list of indications
18 years of age or older of either sex
Able to provide written informed consent
Able to tolerate the physical and logistical requirements of completing a Positron Emission Tomography (PET)scan
Karnofsky score > 60
Women who are nursing may be included in the study if they are able to discontinue breast feeding for 12 hours

Exclusion criteria

Age <18 years
Pregnant women; if there is a possibility of pregnancy, bloodwork will be drawn to definitively establish pregnancy status
Women who are unwilling or unable to discontinue breast feeding for 12 hours post 18F-Fluorodeoxyglucose(FDG) administration
Subjects who are medically unstable
Subjects unwilling to provide informed consent.
Subjects who exceed the safe weight limit of the Positron Emission Tomography (PET) imaging bed or who cannot fit through the PET scanner bore